Cullinan Capital Surpluse from 2010 to 2025
| CGEM Stock | USD 8.30 0.24 2.81% |
Capital Surpluse | First Reported 2010-12-31 | Previous Quarter 673.1 M | Current Value 643.5 M | Quarterly Volatility 25.7 M |
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 56.7 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.86, Ptb Ratio of 0.88 or Days Sales Outstanding of 0.0. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
Cullinan | Capital Surpluse |
Latest Cullinan Oncology's Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Cullinan Oncology LLC over the last few years. It is Cullinan Oncology's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cullinan Oncology's overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Cullinan Capital Surpluse Regression Statistics
| Arithmetic Mean | 593,990,294 | |
| Geometric Mean | 593,502,515 | |
| Coefficient Of Variation | 4.32 | |
| Mean Deviation | 16,082,014 | |
| Median | 584,714,000 | |
| Standard Deviation | 25,686,832 | |
| Sample Variance | 659.8T | |
| Range | 88.4M | |
| R-Value | 0.56 | |
| Mean Square Error | 487.6T | |
| R-Squared | 0.31 | |
| Significance | 0.03 | |
| Slope | 3,005,062 | |
| Total Sum of Squares | 9897.2T |
Cullinan Capital Surpluse History
About Cullinan Oncology Financial Statements
Cullinan Oncology investors utilize fundamental indicators, such as Capital Surpluse, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 673.1 M | 643.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Cullinan Oncology Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.